Nivolumab/relatlimab
http://dbpedia.org/resource/Nivolumab/relatlimab an entity of type: Thing
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022.
rdf:langString
rdf:langString
Nivolumab/relatlimab
xsd:integer
70348402
xsd:integer
1123137155
rdf:langString
None
rdf:langString
Lymphocyte activation gene-3 blocking antibody
rdf:langString
Programmed death receptor-1 blocking antibody
rdf:langString
Nivolumab
rdf:langString
Relatlimab
rdf:langString
D12334
rdf:langString
Rx-only
rdf:langString
Opdualag
rdf:langString
combo
rdf:langString
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022.
rdf:langString
Nivolumab and relatlimab
rdf:langString
S4
rdf:langString
Rx-only
xsd:nonNegativeInteger
8103
rdf:langString
Opdualag
xsd:string
D12334